Rituxan is a type of antibody therapy, which can be used alone or with chemotherapy. It will work in several ways to find and attack the cells where cancer begins.
It is said to target and attach to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells.
At present, Genentech is recruiting patients in a PEMPHIX phase III study for pemphigus vulgaris, which is a disease with limited treatment options.
In 2015, the company also secured orphan drug status to Rituxan to treat pemphigus vulgaris.
Genentech chief medical officer and global product development head Sandra Horning said: “People with pemphigus vulgaris need more options and we look forward to working with the FDA to make Rituxan available to patients with this potentially deadly disease.
“We are committed to developing therapies that target B cells in areas of unmet need across a range of immune and malignant diseases, including new antibody constructs that enhance efficacy, safety or both.”
Earlier this year, Genentech’s Lucentis was approved by the FDA to treat patients with myopic choroidal neovascularization (mCNV).
Lucentis is claimed to be the first FDA-approved anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV in the US.
Last October, Roche along with Chugai Pharmaceutical secured breakthrough therapy status from the FDA for Actemra/RoActemra (tocilizumab) for giant cell arteritis (GCA).
GCA is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its branches.
Image: Genentech in South San Francisco, US. Photo: courtesy of F. Hoffmann-La Roche Ltd.